» Articles » PMID: 27738656

Combination of an Integrin-Targeting NIR Tracer and an Ultrasensitive Spectroscopic Device for Intraoperative Detection of Head and Neck Tumor Margins and Metastatic Lymph Nodes

Overview
Journal Tomography
Publisher MDPI
Specialty Radiology
Date 2016 Oct 15
PMID 27738656
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Despite major advances in targeted drug therapy and radiation therapy, surgery remains the most effective treatment for most solid tumors. The single most important predictor of patient survival is a complete surgical resection of the primary tumor, draining lymph nodes, and metastatic lesions. Presently, however, 20%-30% of patients with head and neck cancer who undergo surgery still leave the operating room without complete resection because of missed lesions. Thus, major opportunities exist to develop advanced imaging tracers and intraoperative instrumentation that would allow surgeons to visualize microscopic tumors during surgery. The cell adhesion molecule integrin v3 is specifically expressed by tumor neovasculature and invading tumor cells, but not by quiescent vessels or normal cells. Here we report the combined use of an integrin-targeting near-infrared tracer (RGD-IRDye800CW) and a handheld spectroscopic device, an integrated point spectroscopy with wide-field imaging system, for highly sensitive detection of integrin overexpression on infiltrating cancer cells. By using an orthotopic head and neck cancer animal model, we show that this tracer-device combination allows intraoperative detection of not only invasive tumor margins but also metastatic lymph nodes. Correlated histological analysis further reveals that microscopic clusters of 50-100 tumor cells can be detected intraoperatively with high sensitivity and specificity, raising new possibilities in guiding surgical resection of microscopic tumors and metastatic lymph nodes.

Citing Articles

Real-time cancer detection with an integrated lensless fluorescence contact imager.

Papageorgiou E, Zhang H, Giverts S, Park C, Boser B, Anwar M Biomed Opt Express. 2018; 9(8):3607-3623.

PMID: 30338143 PMC: 6191610. DOI: 10.1364/BOE.9.003607.


Real-time near-infrared fluorescence imaging using cRGD-ZW800-1 for intraoperative visualization of multiple cancer types.

Handgraaf H, Boonstra M, Prevoo H, Kuil J, Bordo M, Boogerd L Oncotarget. 2017; 8(13):21054-21066.

PMID: 28416744 PMC: 5400565. DOI: 10.18632/oncotarget.15486.

References
1.
Kotwall C, Sako K, Razack M, Rao U, BAKAMJIAN V, SHEDD D . Metastatic patterns in squamous cell cancer of the head and neck. Am J Surg. 1987; 154(4):439-42. DOI: 10.1016/0002-9610(89)90020-2. View

2.
Friedlander M, Theesfeld C, Sugita M, Fruttiger M, Thomas M, Chang S . Involvement of integrins alpha v beta 3 and alpha v beta 5 in ocular neovascular diseases. Proc Natl Acad Sci U S A. 1996; 93(18):9764-9. PMC: 38503. DOI: 10.1073/pnas.93.18.9764. View

3.
Sampath L, Kwon S, Ke S, Wang W, Schiff R, Mawad M . Dual-labeled trastuzumab-based imaging agent for the detection of human epidermal growth factor receptor 2 overexpression in breast cancer. J Nucl Med. 2007; 48(9):1501-10. DOI: 10.2967/jnumed.107.042234. View

4.
Zhang X, Xiong Z, Wu Y, Cai W, Tseng J, Gambhir S . Quantitative PET imaging of tumor integrin alphavbeta3 expression with 18F-FRGD2. J Nucl Med. 2006; 47(1):113-21. PMC: 4160026. View

5.
Smith A, Mancini M, Nie S . Bioimaging: second window for in vivo imaging. Nat Nanotechnol. 2009; 4(11):710-1. PMC: 2862008. DOI: 10.1038/nnano.2009.326. View